Spain: Almirall targets M&A with €200m capital increase

Almirall, a global biopharmaceutical company focused on skin health, has raised €200m (US$216m) in a new share issue following completion of an accelerated book-building process carried out by joint global coordinators and bookrunners JP Morgan and BNP Paribas. Proceeds will provide the company with ongoing financial flexibility and the financial resources to actively pursue and…

You must be a HMI Subscriber to view this content.

Subscribe Now »